{"id":"7ca99c03-1fc1-4b26-8760-e932c8a325a8","kind":"institutions","code":"UB-I6579","name":"Chengdu Ke Venture Capital","nameBasis":"transliterated","summary":"Chengdu Ke Venture Capital is a domestic state-capital-backed investment guidance fund supporting technology companies through equity investment.","description":"Chengdu Ke Venture Capital is a domestic state-capital-backed investment guidance fund supporting technology companies through equity investment.","country":null,"category":null,"originalName":"成都科创投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:32:23.042Z","englishUpdatedAt":"2026-10-15T17:35:39.279Z","reviewedAt":"2026-10-15T17:35:39.279Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"cf254128ac493c10c818a2dd911576d872da8b629dce71fcc9926ae8ba5b6185","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"成都科创投是国内国资背景投资引导基金，通过股权投资支持科创企业发展。","sources":[],"related":[{"id":"294a53e9-660f-4de9-b6cd-a780303aea4c","kind":"news","code":"294a53e9-660f-4de9-b6cd-a780303aea4c","name":"DexForce raises RMB 1 billion in Series B financing","nameBasis":"translated-title","summary":"On 2026-06-30, according to Xiniu Data, DexForce completed Series B financing, raising RMB 1 billion. Investors were Shen Venture Capital, Guiyangjingjikaifaqu Industry Development Investment Group, Qianhaimu Fund, Changsha Qunxin Investment Consulting Co., Ltd., Gongyin Capital, Hengjian Holdings, Zhurui Capital, Nanshanzhanxintou, Chengdu Ke Venture Capital, Sichuan Yuanshi Fund and others. The company is a developer of highly generalizable embodied intelligence technology.","description":"","country":null,"category":null,"originalName":"跨维智能完成B轮融资，金额10亿人民币","eventDate":"2026-06-30T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T15:38:28.763Z","englishUpdatedAt":"2026-10-15T20:48:35.134Z","reviewedAt":"2026-10-15T20:48:35.134Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"b42fb76bf9b9827de27356524849e38b182979daa8a2133f3feb2c2a1a454425","companyId":"75de0018-e486-48cc-a3ee-dc5f35c9ca82","foundedYear":null,"logoUrl":null,"path":"/news/294a53e9-660f-4de9-b6cd-a780303aea4c"},{"id":"bb6133e6-8d89-4ce5-a650-f75ce83a7a5a","kind":"news","code":"bb6133e6-8d89-4ce5-a650-f75ce83a7a5a","name":"VAST raises USD 150 million in Series A+ financing","nameBasis":"translated-title","summary":"On 2026-07-02, according to Xiniu Data, VAST completed Series A+ financing, raising USD 150 million. Investors were Jili Capital, Fuxingchuangfu, Ceyuan Capital, Yingce Capital, Yuansheng Capital, Sisanjiujiu, Tanwan, Juren Network, Yizhuangguotou, Jishi Capital, Yida Capital, Chengdu Ke Venture Capital, Huakong Fund, Xi Venture Capital, Muhuakechuang and others. The company is a developer of general-purpose AI 3D large models.","description":"","country":null,"category":null,"originalName":"VAST完成A+轮融资，金额1.50亿美元","eventDate":"2026-07-02T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-16T19:44:30.302Z","englishUpdatedAt":"2026-10-18T08:52:13.929Z","reviewedAt":"2026-10-18T08:52:13.929Z","snapshotAt":"2026-10-18T08:51:49.337Z","sourceHash":"bcd8315025331540be8f9602a8e6be358063e6e796e729bcbee0133fbe8435eb","companyId":"e5bb70ce-6362-47b9-959f-e05828ac2fab","foundedYear":null,"logoUrl":null,"path":"/news/bb6133e6-8d89-4ce5-a650-f75ce83a7a5a"},{"id":"48c7fbb5-da1d-4d8f-8891-16287b8388df","kind":"news","code":"48c7fbb5-da1d-4d8f-8891-16287b8388df","name":"iRegene raises RMB 260 million in Series C+ financing","nameBasis":"translated-title","summary":"On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.","description":"","country":null,"category":null,"originalName":"睿健医药完成C+融资，金额2.60亿人民币","eventDate":"2026-07-02T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T17:18:19.314Z","englishUpdatedAt":"2026-10-15T19:44:30.495Z","reviewedAt":"2026-10-15T19:44:30.495Z","snapshotAt":"2026-10-15T18:31:34.288Z","sourceHash":"04f75ff6eebec70ebd15f157502b7c04b5ba291c00be05f07b05087ccb13186c","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"path":"/news/48c7fbb5-da1d-4d8f-8891-16287b8388df"}],"path":"/institutions/chengdu-ke-venture-capital","displayName":"成都科创投","displayNameLang":"zh","structured":{"city":null,"country":"China (mainland)","location":null,"role":null,"category":null,"company":null},"definition":"成都科创投 is a government guidance fund based in China (mainland) with 3 recorded investments in 3 companies.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/institutions/chengdu-ke-venture-capital"}